Search hospitals > Pennsylvania > Wynnewood
Lankenau Medical Center
Claim this profileWynnewood, Pennsylvania 19096
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
346 reported clinical trials
22 medical researchers
Summary
Lankenau Medical Center is a medical facility located in Wynnewood, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Lankenau Medical Center is involved with conducting 346 clinical trials across 383 conditions. There are 22 research doctors associated with this hospital, such as Albert DeNittis, MD, Paul B. Gilman, William Gray, MD, and Basel Ramlawi, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 positive
HER2 negative
Top PIs
Albert DeNittis, MDLankenau Medical Center4 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
59 reported clinical trials
120 drugs studied
Paul B. GilmanRiddle Memorial Hospital3 years of reported clinical research
Studies Cancer
Studies Non-Small Cell Lung Cancer
14 reported clinical trials
43 drugs studied
William Gray, MDLankenau Medical Center6 years of reported clinical research
Studies Tricuspid Regurgitation
Studies Mitral Valve Regurgitation
10 reported clinical trials
15 drugs studied
Basel Ramlawi, MDLankenau Medical Center2 years of reported clinical research
Studies Mitral Valve Regurgitation
Studies Aortic Valve Stenosis
9 reported clinical trials
14 drugs studied
Clinical Trials running at Lankenau Medical Center
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Ovarian Cancer
Pancreatic Cancer
Fallopian Tube Cancer
Small Cell Lung Cancer
Squamous Cell Carcinoma
Endometrial Cancer
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Lankenau Medical Center?
Lankenau Medical Center is a medical facility located in Wynnewood, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Lankenau Medical Center is involved with conducting 346 clinical trials across 383 conditions. There are 22 research doctors associated with this hospital, such as Albert DeNittis, MD, Paul B. Gilman, William Gray, MD, and Basel Ramlawi, MD.
Where is Lankenau Medical Center located?
To reach Lankenau Medical Center in Wynnewood, Pennsylvania:
1. Take I-95 to I-676/76 West in Philadelphia.
2. Exit onto City Avenue and head south on Route 1 (City Line Avenue) to the intersection of Route 30 (Lancaster Avenue).
3. Turn right onto Lancaster Avenue; the hospital will be on your left. Alternatively, utilize GPS navigation services like Waze for real-time directions.
Who should I call to ask about financial aid or insurance network?
**Lankenau Medical Center Financial Assistance:**
- Contact the Main Line Health Business office at 484.337.1970 for financial assistance inquiries.
- Financial assistance is available based on annual income and household size, with 100% assistance for those with income 300% or less of the federal poverty guidelines, and significant discounts for those with income between 300% and 500%.
- Financial counselors are available to assist with the application process.
**NYU Langone Health Insurance Information:**
- Visit the NYU Langone Health website for detailed information on insurance, billing, and financial assistance.
- It's recommended to consult with your insurance company for accurate out-of-pocket costs for services at NYU Langone.
- In emergency situations or when treated by an out-of-network provider at an in-network hospital, you're protected from being charged beyond your plan’s copayments, coinsurance, or deductible.
What insurance does Lankenau Medical Center accept?
Lankenau Medical Center, part of Main Line Health, accepts a broad spectrum of health insurance plans. This includes commercial plans such as Aetna, Cigna, Capital Blue Cross, Highmark Blue Shield, Independence Blue Cross, and United Healthcare. They also welcome Medicare Advantage plans like Advantra Medicare (Aetna), Humana Medicare Advantage, and USA MCO, in addition to Medicaid MCO plans such as AmeriHealth Caritas and PA Health and Wellness.
What awards or recognition has Lankenau Medical Center received?
Lankenau Medical Center has been awarded a Silver Milestone recognition by the Intersocietal Accreditation Commission (IAC) for 25 years of IAC Echocardiography accreditation. It was also ranked No. 168 in Newsweek's list of the nation's best hospitals, recognized for attracting top talent, delivering excellent patient outcomes, and pioneering advanced therapies and research.